Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Pharmacology & Therapeutics|May 7, 2015
Glioblastoma multiforme: Pathogenesis and treatmentConstantinos Alifieris, Dimitrios T TrafalisPersonalized Medicine|December 1, 2022
Refining personalized diagnosis, treatment and exploitation of hypothyroidism related to solid nonthyroid cancerMaria V Deligiorgi, Dimitrios T TrafalisExpert Opinion on Biological Therapy|July 14, 2020
Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspectiveMaria V Deligiorgi, Dimitrios T TrafalisExpert Opinion on Drug Safety|December 8, 2020
The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learnMaria V Deligiorgi, Dimitrios T TrafalisInternational Immunopharmacology|October 18, 2020
Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse eventMaria V Deligiorgi, Dimitrios T TrafalisInternational Journal of Molecular Sciences|January 11, 2022
The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving ResearchMaria V Deligiorgi, Dimitrios T TrafalisInternational Journal of Molecular Sciences|April 28, 2023
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint InhibitorsMaria V Deligiorgi, Dimitrios T TrafalisJournal of Clinical Medicine|June 24, 2022
The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing ConundrumMaria V Deligiorgi, Dimitrios T TrafalisExpert Review of Clinical Pharmacology|June 27, 2022
The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologistsMaria V Deligiorgi, Dimitrios T TrafalisPharmacology & Therapeutics|October 1, 2018
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapyAnastasia Constantinidou, Constantinos Alifieris, Dimitrios T TrafalisPageof 7